Status:
TERMINATED
Anti-anxiety Biotics for Breast Cancer Survivors
Lead Sponsor:
Auburn University
Collaborating Sponsors:
National Center for Advancing Translational Sciences (NCATS)
Conditions:
Anxiety Generalized
Breast Cancer Female
Eligibility:
FEMALE
50+ years
Phase:
NA
Brief Summary
Cancer survivors experience more rapid declines in health-related quality of life which include physical and psychological comorbidities, the latter of which may be subclinical and often overlooked by...
Eligibility Criteria
Inclusion
- Female breast cancer survivors or female relatives of a breast cancer survivor who:
- are 50 years of age or older
- have completed primary treatment
- currently experience clinical anxiety symptoms determined by the 7 item Generalized Anxiety Disorder screener (GAD-7; eligibility requires a total score of 5 or higher on the 21 point scale)
- agree not to change dietary supplements throughout the course of the study
- are willing to comply with daily supplement regimen
- are able to speak and read English.
Exclusion
- use of any of the following drugs within the last 4 weeks (unless indefinitely prescribed): systemic antibiotics, corticosteroids, immunosuppressive agents, or commercial probiotics
- changes in treatment for anxiety symptoms (i.e. initiation of Cognitive Behavior Therapy (CBT) within the last four weeks
- current use (within 12 weeks) of anxiolytic medications.
Key Trial Info
Start Date :
July 20 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2022
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT04784182
Start Date
July 20 2021
End Date
May 1 2022
Last Update
August 24 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Auburn University
Auburn, Alabama, United States, 36849